Amniotic's platform enables the extraction of Mesenchymal Stem Cells (MSC) from amniotic fluid, which is recovered from healthy voluntary donors in connection with planned caesarean sections
Amniotics has a project portfolio where the same technology and methodology can be applied for various indications
Our procedure for collecting term amniotic fluid from voluntary healthy donors is performed at full-term planned caesarean deliveries
Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Amniotics is looking to establish strategic partnerships with researchers and companies to accelerate the development of our stem-cell-based therapies to the benefit of patients. See our pipeline here.
Regulatory
September 23, 2024
Regulatory
September 23, 2024
Bolagsverket har lämnat tillstånd att verkställa fusionsplanen mellan Magle group och Amniotics
June 5, 2024
Video interview - Amniotics CEO Marcus Larsson and Magle Group CEO Justin Pierce.
February 14, 2024
CEO Marcus Larsson presents at Redeye Regenerative Medicine/Cell Therapy Event
February 14, 2024
Latest report
